Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 3
2006 6
2007 1
2008 4
2009 2
2010 2
2011 1
2012 5
2013 1
2014 5
2015 4
2016 2
2017 1
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 3 …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate o …
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Bago Rožanković P, et al. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. Cogn Behav Neurol. 2021. PMID: 34851866 Clinical Trial.
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We conducted a prospective, randomized, 6-month clinical trial involving 85 individuals with moderate AD divided into two groups: group 1 (n = 42 …
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We co …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. ...CONCLUSIONS: In patients with moderate to severe AD receiving stable doses of donepezil, mema …
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable …
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Knapp M, et al. Int J Geriatr Psychiatry. 2017 Dec;32(12):1205-1216. doi: 10.1002/gps.4583. Epub 2016 Oct 13. Int J Geriatr Psychiatry. 2017. PMID: 27739182 Free PMC article. Clinical Trial.
A total of 295 community-dwelling patients with moderate/severe Alzheimer's disease, already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii) discontinue donepezil and start memantine; or (iv) …
A total of 295 community-dwelling patients with moderate/severe Alzheimer's disease, already treated with donepezil, were randomised …
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP. Howard R, et al. Lancet Neurol. 2015 Dec;14(12):1171-81. doi: 10.1016/S1474-4422(15)00258-6. Epub 2015 Oct 27. Lancet Neurol. 2015. PMID: 26515660 Clinical Trial.
METHODS: In the randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial, community-living patients with moderate-to-severe Alzheimer's disease (who had been prescribed donepezil continuo …
METHODS: In the randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease …
Memantine hydrochloride: pharmacological and clinical profile.
Möbius HJ, Stöffler A, Graham SM. Möbius HJ, et al. Drugs Today (Barc). 2004 Aug;40(8):685-95. Drugs Today (Barc). 2004. PMID: 15510240 Clinical Trial.
Recently completed clinical studies demonstrate positive effects of memantine in Alzheimer's disease both as a monotherapy and in patients receiving continuous donepezil treatment. ...More recently, memantine was approved in the US for the treatment of modera …
Recently completed clinical studies demonstrate positive effects of memantine in Alzheimer's disease both as a monotherapy and in pat …
Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.
Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Periclou AP, et al. Ann Pharmacother. 2004 Sep;38(9):1389-94. doi: 10.1345/aph.1D638. Epub 2004 Jul 20. Ann Pharmacother. 2004. PMID: 15266045 Clinical Trial.
Two subjects withdrew due to adverse events while taking donepezil alone. Single memantine doses administered with multiple donepezil doses were well tolerated. CONCLUSIONS: The pharmacokinetic and pharmacodynamic data from this study indicated a lack of inte …
Two subjects withdrew due to adverse events while taking donepezil alone. Single memantine doses administered with multiple …
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team. Jones R, et al. Trials. 2009 Jul 24;10:57. doi: 10.1186/1745-6215-10-57. Trials. 2009. PMID: 19630974 Free PMC article. Clinical Trial.
BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely p …
BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug c …
[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial].
Hu HT, Zhang ZX, Yao JL, Yu HZ, Wang YH, Tang HC, Ji CJ, Xu T. Hu HT, et al. Zhonghua Nei Ke Za Zhi. 2006 Apr;45(4):277-80. Zhonghua Nei Ke Za Zhi. 2006. PMID: 16780671 Clinical Trial. Chinese.
METHODS: One hundred patients with diagnosis of possible or probable AD and Mini Mental State Examination total scores between 10 and 26 from 6 centers in two cities of China were randomly divided into two groups: akatinol memantine group (n = 50, given akatinol memanti …
METHODS: One hundred patients with diagnosis of possible or probable AD and Mini Mental State Examination total scores between 10 and 26 fro …
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Modrego PJ, et al. Eur J Neurol. 2010 Mar;17(3):405-12. doi: 10.1111/j.1468-1331.2009.02816.x. Epub 2009 Oct 28. Eur J Neurol. 2010. PMID: 19874395 Clinical Trial.
BACKGROUND AND PURPOSE: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain me …
BACKGROUND AND PURPOSE: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical vie …
40 results